These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease. Silver DE; Trosch RM Neurology; 2016 Apr; 86(14 Suppl 1):S25-35. PubMed ID: 27044647 [TBL] [Abstract][Full Text] [Related]
27. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings. Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761 [No Abstract] [Full Text] [Related]
34. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Dhall R; Kreitzman DL Neurology; 2016 Apr; 86(14 Suppl 1):S13-24. PubMed ID: 27044646 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease. Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205 [TBL] [Abstract][Full Text] [Related]
36. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease. Greig SL; McKeage K CNS Drugs; 2016 Jan; 30(1):79-90. PubMed ID: 26692288 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients. Mizutani Y; Okada Y; Ogawa M; Hasegawa T; Nabeshima T Biol Pharm Bull; 1995 Dec; 18(12):1729-37. PubMed ID: 8787797 [TBL] [Abstract][Full Text] [Related]